No prior TDF therapy (participants may have received prior interferon or oral anti-HBV nucleoside/nucleotide therapy; participants must have discontinued interferon therapy ≥ 6 months prior to screening; participants experienced on anti-HBV nucleoside/nucleotide therapy must have discontinued therapy ≥ 16 weeks prior to screening to avoid flare if randomized to the placebo arm)
You may not be if
Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study
Males and females of reproductive potential who are not willing to use an effective method of contraception during the study
Decompensated liver disease
Receipt of interferon (pegylated or not) therapy within 6 months of the Screening Visit
Receipt of anti-HBV nucleoside/nucleotide therapy within 16 weeks of the Screening Visit
Alpha fetoprotein \> 50 ng/mL
Evidence of hepatocellular carcinoma (HCC)
Coinfection with HIV, hepatitis C virus (HCV), or hepatitis D virus (HDV)
History of significant renal disease (eg, nephrotic syndrome, renal dysgenesis, polycystic kidney disease, congenital nephrosis, acute tubular necrosis, other renal disease)
History of significant bone disease (eg, osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, osteochondroses, multiple bone fractures)
Significant cardiovascular, pulmonary, or neurological disease
Evidence of a gastrointestinal malabsorption syndrome that may interfere with absorption of orally administered medications
History of solid organ or bone marrow transplantation
Ongoing therapy with nephrotoxic agents, competitors of renal excretion, systemic chemotherapeutic agents, systemic corticosteroids, interleukin-2 (IL-2), or other immunomodulating or investigational agents
Known hypersensitivity to the study drugs, the metabolites or formulation excipients
Any other condition (including alcohol or substance abuse) or prior therapy that, in the opinion of the Investigator, would make the participants unsuitable for the study or unable to comply with dosing requirements
